Adalta Ltd. · ASX:1AD
Adalta — Investor Presentation (July 2020)
25 slides from Adalta's investor presentation, Jul 30, 2020
Slide 1: i-bodies: drugging difficult targets for next generation protein therapeutics
i-bodies: drugging difficult targets for next generation protein therapeutics Investor Presentation Jul-Aug 2020 AdAlta Limited (ASX:1AD) Tim Oldham, CEO and Managing Director t.oldham@adalta.com.au
Slide 2: Disclaimer
Disclaimer Investment in AdAlta is subject to investment risk, including possible loss of income and capital invested. AdAlta does not guarantee any particular rate of return or performance, nor do they guarantee the repayment of capital. This presentation is not an offer or invitation for subscript
Slide 3: AdAlta: clinical stage company, validated platform for asset creation, unique lead asset
AdAlta: clinical stage company, validated platform for asset creation, unique lead asset 4 Process to create additional valuable assets Build pipeline assets in methodical way with validated technology: ✓ AD-214 indications and partnering ✓ Internal pipeline products: G-protein coupled receptors (GP
Slide 4: i-bodies: in clinic for "difficult to drug" targets
i-bodies: in clinic for “difficult to drug” targets CDR3 CDR3 CDR1 Shark CDR1 Human Human hNCAM i-body Shark VNAR* Ribbon overlay Domain 1 library Unique i-body properties Advantage over traditional antibodies • Small size, long binding loop • Access to unique epitopes (binding sites) • Novel, tunab
Slide 5: Lead product AD-214: first-in-class anti-fibrotic
Lead product AD-214: first-in-class anti- fibrotic Strong biological rationale: CXCR4 receptor is AD-214 is the only CXCR4 antagonist critical player in, and biomarker of, development of being developed for fibrosis fibrosis in many organs Novel mode of action: inhibits migration of inflammatory, fi
Slide 6: Lead indication IPF: $3b market, poor options
Lead indication IPF: $3b market, poor options Idiopathic Pulmonary Fibrosis (IPF) is irreversible, unpredictable, incurable >300,000 people living with IPF 40,000 people die from IPF every year 3.8 years median survival after diagnosis Safety, efficacy limitations with current treatments Burden of f
Slide 7: AD-214: road to the clinic
AD-214: road to the clinic CXCR4 6 Statistical significance# to 21d bleomycin Receptor Occupancy - All animals Vehicle 5 120 10 mg/kg 30 mg/kg ns ns ns ns 100 mg/kg 100 4 Ashcroft Score Percent receptor occupancy 80 * * ** ** ** 3 60 2 40 20 1 0 0 Naïve 21 day 30 mg/kg 30 mg/kg 60 mg/kg 0.01 mg/kg 1
Slide 8: Three-part phase I design
Three-part phase I design* Part A Molecular Part B Imaging with CXCR4-Gallium-68-Pentixafor PET Part C Objectives (Ongoing correlates toGAP with earlyIndex 2021)and Treatment (early 2021 to late Effects 2021) in IPF (late 2021 to mid-2022) Single dose, Antje Prasse1, Danny Jonigk2, Tobias Welte1, Be
Slide 9: Pipeline: diverse target capability supports internal and external pipeline assets
Pipeline: diverse target capability supports internal and external pipeline assets i-body platform capability Commercial validation GPCRs Chemokine • i-body libraries, IP • Target Brings >20 targets to which i-body • Discovery, • Pre-clinical, clinical Other binders* have Lysophos- Does development
Slide 10: AdAlta's twin strategies to create valuable assets from the i-body platform
AdAlta’s twin strategies to create valuable assets from the i-body platform A In-house pipeline Licence to pharma of drug candidates Major upfronts + milestones i-body products in defined & royalties ”sweet spot” Invest to value inflection (typically Phase I or II) Multiple i-body i-body drugs and t
Slide 11: Single domain antibody platform potential: Ablynx case study
Single domain antibody platform potential: Ablynx case study Ablynx strategy (2007) A. Leverage platform to rapidly identify potential drug candidates B. Drive lead product candidate through clinical development C. Selectively partner to maximize market opportunity D. Maintain and expand technology
Slide 12: Growth trajectory to build value
Growth trajectory to build value C Accelerate (from ~mid-2021) B Expand A (~mid 2020 to late 2021) Maximise catalysts from current funded base (2020) Market Cap: A$18 million (24 July 2020) From … Via … Towards 2023 … • i-body platform in clinic for difficult • Laying the foundations for growth • Mu
Slide 13: Key execution milestones
Key execution milestones Strategic 2020 YTD achievements H2 2020 H1 2021 H2 2021 priority US patent Phase I Part A (HV) Phase I Part A (HV): top Phase I Part C (ILD) interim drug safety line safety, PK/PD first patient multi-dose Pre-clinical efficacy, committee findings* results* PK/PD First partne
Slide 14: Experienced board and advisors
Experienced board and advisors Board Scientific Advisory Board Dr Paul MacLeman Tim Oldham, PhD Brian Richardson Chair CEO & Managing Director Drug discovery and development expert Liddy McCall Dr Robert Peach Steve Felstead (alt: Dr James Williams) Independent Director Clinical development Director
Slide 15: AdAlta (ASX:1AD) investment proposition
Molecular Imaging with CXCR4-Gallium-68-Pentixa correlates with GAP Index and Treatment Effects i Antje Prasse1, Danny Jonigk2, Tobias Welte1, Benedikt Jäger1, Frank B AdAlta (ASX:1AD) investment proposition 1Pneumology, Hannover Medical School; Fraunhofer ITEM, DZL BREAT 2Pathology, Hannover Medica
Slide 16: Contacts for more information
Contacts for more information: Tim Oldham, CEO and Managing Director t.oldham@adalta.com.au www.adalta.com.au
Slide 17: Appendix
M AdAlta next generation protein therapeutics APPENDIX
Slide 18: Financial position and results
Financial position and results Key financial details Share price performance (last 12 months) 5.00 0.25 ASX code 1AD 4.00 0.20 Share price (24 July 2020) AUD$0.115 Share Priec (A$) Volume (m) 3.00 0.15 Market capitalisation AUD$18.85m 2.00 0.10 Ordinary Shares 163,945,613 Listed Options 23,348,803 1
Slide 19: Market benchmarks: reaching for the stars!
Market benchmarks: reaching for the stars! Fibrosis Nov-19 acquired by Roche Jan-20 platform license by Jul-19 license by Boehringer $390m + $1b – Phase II Boehringer Ingelheim pipelines Ingelheim €45m + €1.1b Aug-15 BMS option to buy $?m + $1b milestones Phase I $150m + $1.25b milestones Preclinica
Slide 20: Breadth and depth in executive leadership
Breadth and depth in executive leadership Executive Tim Oldham, PhD Mick Foley, PhD CEO & Managing Director Chief Scientific Officer Dallas Hartman, PhD Claudia Gregorio-King, PhD Chief Operating Officer VP Clinical Product Development Kevin Lynch, MD Consultant Medical Expert 20
Slide 21: Near term strategic priorities (expansion phase)
Near term strategic priorities (expansion phase) Create value inflections for lead asset AD-214 • Clinical development in IPF/ILD • Expand indications, create licensing options Add 2 assets to internal pipeline in our “sweet spot” • G-protein coupled receptors (GPCRs) • Fibrosis, inflammation, cance
Slide 22: NHP GLP toxicology: AD-214 safe
NHP GLP toxicology: AD-214 safe 3 non-human primate studies completed Good Laboratory Practice (GLP) study to evaluate safety and toxicology prior to initial human studies – 10mg/kg, 30mg/kg and 100mg/kg multiple doses over four weeks plus recovery (human equivalent dose 32mg/kg) – AD-214 well toler
Slide 23: Non-human primate GLP toxicology: Phase I dose justification
Non-human primate GLP toxicology: Phase I dose justification Pharmacokinetics Pharmacodynamics • Elimination half-life 22-29h • >60% receptor occupancy* for 72h at >30mg/kg • Human equivalent: ~71h (estimate) • Human equivalent: ~10mg/kg (estimate) • AD-214 available for >3 days • High receptor bind
Slide 24: AD-214 induced reduction in progression of fibrosis in mouse bleomycin model
AD-214 induced reduction in progression of fibrosis in mouse bleomycin model 6 AD-214 reduced Ashcroft Score with Statistical significance# to 21d bleomycin statistical significance compared to 5 bleomycin treated mice at: ns ns ns ns – 1-30mg/kg every second day 4 Ashcroft Score * * ** ** ** – 10-3
Slide 25: Three-part phase I design
Three-part phase I design* Phase I, dose-escalating study of the safety, tolerability, PK & PD of single and repeat doses of AD-214 in healthy volunteers (HVs) and patients with interstitial lung disease (ILD) Part A Molecular Part B Imaging with CXCR4-Gallium-68-Pentixafor PET Part C Objectives (On